Real-World data to reveal IBI351's impact on tough lung cancer

NCT ID NCT07198620

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at medical records of 600 Chinese patients with advanced non-small cell lung cancer that has a KRAS G12C mutation. All patients took the drug IBI351 between August 2024 and August 2025. Researchers will check how many patients' tumors shrank or disappeared, how long they lived without the cancer getting worse, and what side effects occurred. The goal is to see how well IBI351 works in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,

    Guangzhou, Guangdong, 510080, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••